[go: up one dir, main page]

MA32481B1 - Compositions et procédés d'utilisation pour des anticorps thérapeutiques - Google Patents

Compositions et procédés d'utilisation pour des anticorps thérapeutiques

Info

Publication number
MA32481B1
MA32481B1 MA33525A MA33525A MA32481B1 MA 32481 B1 MA32481 B1 MA 32481B1 MA 33525 A MA33525 A MA 33525A MA 33525 A MA33525 A MA 33525A MA 32481 B1 MA32481 B1 MA 32481B1
Authority
MA
Morocco
Prior art keywords
compositions
methods
antibodies
therapeutic antibodies
baffr
Prior art date
Application number
MA33525A
Other languages
Arabic (ar)
English (en)
Inventor
Christoph Heusser
Julia Neugebauer
Eveline Schaadt
Stefanie Urlinger
Maximilian Woisetschlaeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41073830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32481(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32481B1 publication Critical patent/MA32481B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention porte sur des anticorps qui se lient de façon spécifique au récepteur baff (baffr). Plus spécifiquement, l'invention porte sur des anticorps qui sont des antagonistes de baffr avec une activité de déplétion des cellules b in vivo, et sur des compositions et procédés d'utilisation pour lesdits anticorps pour traiter des troubles pathologiques qui peuvent être traités par destruction ou déplétion des cellules b, tels que le lupus érythémateux systémique ou la polyarthrite rhumatoïde ou d'autres maladies auto-immunes, des lymphomes, des leucémies ou des myélomes.
MA33525A 2008-07-17 2011-01-14 Compositions et procédés d'utilisation pour des anticorps thérapeutiques MA32481B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08160671 2008-07-17
EP09160326 2009-05-15
PCT/EP2009/059030 WO2010007082A1 (fr) 2008-07-17 2009-07-15 Compositions et procédés d'utilisation pour des anticorps thérapeutiques

Publications (1)

Publication Number Publication Date
MA32481B1 true MA32481B1 (fr) 2011-07-03

Family

ID=41073830

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33525A MA32481B1 (fr) 2008-07-17 2011-01-14 Compositions et procédés d'utilisation pour des anticorps thérapeutiques

Country Status (40)

Country Link
US (3) US8106163B2 (fr)
EP (1) EP2315780B8 (fr)
JP (2) JP5767109B2 (fr)
KR (2) KR101545795B1 (fr)
CN (1) CN102119174B (fr)
AR (1) AR072749A1 (fr)
AU (1) AU2009272771B2 (fr)
BR (1) BRPI0915928B8 (fr)
CA (1) CA2730063C (fr)
CL (1) CL2011000086A1 (fr)
CR (1) CR11863A (fr)
CU (1) CU23878B1 (fr)
CY (1) CY1116800T1 (fr)
DK (1) DK2315780T3 (fr)
DO (1) DOP2011000016A (fr)
EA (1) EA024492B1 (fr)
EC (1) ECSP11010761A (fr)
ES (1) ES2547270T3 (fr)
GE (1) GEP20146129B (fr)
HR (1) HRP20151227T1 (fr)
HU (1) HUE025778T2 (fr)
IL (1) IL210485A (fr)
JO (1) JO3149B1 (fr)
MA (1) MA32481B1 (fr)
MX (1) MX2011000616A (fr)
MY (1) MY158980A (fr)
NI (1) NI201100017A (fr)
NZ (1) NZ590057A (fr)
PE (1) PE20110563A1 (fr)
PL (1) PL2315780T3 (fr)
PT (1) PT2315780E (fr)
RS (1) RS54299B1 (fr)
SG (1) SG193805A1 (fr)
SI (1) SI2315780T1 (fr)
SM (1) SMP201100010B (fr)
SV (1) SV2011003807A (fr)
TW (1) TWI508742B (fr)
UY (1) UY31987A (fr)
WO (1) WO2010007082A1 (fr)
ZA (1) ZA201008952B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
WO2012076670A2 (fr) 2010-12-10 2012-06-14 Novartis Ag Formulation d'anticorps
JP2012153788A (ja) * 2011-01-25 2012-08-16 Nitto Denko Corp 光学用粘着シート
EP3421496B1 (fr) * 2011-05-13 2024-08-07 Astellas Pharma Inc. Anticorps pour le traitement du cancer exprimant du claudin 6
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
WO2015100246A1 (fr) 2013-12-24 2015-07-02 Ossianix, Inc. Composés à liaison sélective baff et procédés associés
EP3099715B1 (fr) 2014-01-31 2020-11-18 Boehringer Ingelheim International GmbH Nouveaux anticorps contre baff
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EP4378957A3 (fr) 2015-07-29 2024-08-07 Novartis AG Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
EP3316902A1 (fr) 2015-07-29 2018-05-09 Novartis AG Polythérapies comprenant des molécules d'anticorps contre tim -3
EP3389712B1 (fr) 2015-12-17 2024-04-10 Novartis AG Molécules d'anticorps anti-pd-1 et leurs utilisations
ES2797091T3 (es) 2016-02-10 2020-12-01 Novartis Ag Uso de inhibidores de la actividad o de la función de la PI3K para el tratamiento del síndrome de Sjögren primario
WO2017214170A2 (fr) * 2016-06-06 2017-12-14 City Of Hope Anticorps baff-r et utilisations de ceux-ci
KR20250016462A (ko) 2016-12-21 2025-02-03 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
US11197928B2 (en) 2017-01-13 2021-12-14 Board Of Regents, The University Of Texas System Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
AU2018271915B2 (en) * 2017-05-24 2025-03-27 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
JP7303126B2 (ja) 2017-06-20 2023-07-04 テネオバイオ， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
CA3101069A1 (fr) * 2018-07-20 2020-01-23 Teneobio, Inc. Anticorps a chaine lourde se liant a cd19
TWI859192B (zh) * 2019-03-29 2024-10-21 日商中外製藥股份有限公司 包含抗il-6受體抗體之bbb功能低下之抑制劑
CN113874398B (zh) 2019-05-21 2025-08-01 诺华股份有限公司 Cd19结合分子及其用途
CA3160207A1 (fr) 2019-11-06 2021-05-14 Novartis Ag Traitement du syndrome de sjogren
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
EP4192870A1 (fr) 2020-08-04 2023-06-14 Novartis AG Traitement de llc
TW202221033A (zh) 2020-08-04 2022-06-01 瑞士商諾華公司 Ｂ細胞惡性腫瘤的治療
CN118459585A (zh) * 2020-09-07 2024-08-09 白先宏 Baff-r结合分子及其应用
EP4240494A1 (fr) 2020-11-06 2023-09-13 Novartis AG Polythérapie à base d'agents anti-cd19 et d'agents de ciblage de lymphocytes b pour traiter des malignités à lymphocytes b
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
CN117203240A (zh) 2021-05-04 2023-12-08 诺华股份有限公司 使用抗baffr抗体治疗狼疮肾炎
JP2024516019A (ja) 2021-05-04 2024-04-11 ノバルティス アーゲー 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療
IL311600A (en) * 2021-09-29 2024-05-01 Dragonfly Therapeutics Inc Antibodies targeting BAFF-R and their use
EP4683948A1 (fr) 2023-03-21 2026-01-28 Biograph 55, Inc. Anticorps multispécifiques cd19/cd38
WO2025058962A1 (fr) * 2023-09-11 2025-03-20 Absci Corporation Procédés à haut rendement pour caractérisation cinétique, quantification et optimisation d'anticorps et d'expression de fragments d'anticorps dans des bactéries
WO2025131888A1 (fr) 2023-12-19 2025-06-26 Basf Se Polyalkylène imines alcoxylées modifiées ou polyamines alcoxylées modifiées

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383154C (fr) * 1999-08-17 2013-04-30 Biogen, Inc. Recepteur de baff (bcma) et agent immunoregulateur
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
JP2008526205A (ja) * 2004-12-31 2008-07-24 ジェネンテック・インコーポレーテッド Ｂｒ３に結合するポリペプチド及びその使用
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides

Also Published As

Publication number Publication date
CA2730063A1 (fr) 2010-01-21
AU2009272771B2 (en) 2012-09-20
BRPI0915928B8 (pt) 2021-05-25
HUE025778T2 (en) 2016-05-30
SI2315780T1 (sl) 2015-11-30
MY158980A (en) 2016-11-30
NI201100017A (es) 2012-08-17
GEP20146129B (en) 2014-08-11
US9340620B2 (en) 2016-05-17
BRPI0915928B1 (pt) 2020-10-20
SMAP201100010A (it) 2011-05-06
JP2015133983A (ja) 2015-07-27
IL210485A (en) 2015-03-31
EA024492B1 (ru) 2016-09-30
US9382326B2 (en) 2016-07-05
CU23878B1 (es) 2013-04-19
PL2315780T3 (pl) 2016-01-29
CN102119174A (zh) 2011-07-06
CA2730063C (fr) 2017-04-18
SG193805A1 (en) 2013-10-30
DOP2011000016A (es) 2011-02-15
RS54299B1 (sr) 2016-02-29
UY31987A (es) 2010-02-26
EP2315780B1 (fr) 2015-08-19
DK2315780T3 (en) 2015-10-19
CR11863A (es) 2011-02-11
EP2315780B8 (fr) 2015-09-23
WO2010007082A1 (fr) 2010-01-21
ZA201008952B (en) 2012-01-25
CU20110013A7 (es) 2012-06-21
SV2011003807A (es) 2011-03-23
KR20110020914A (ko) 2011-03-03
EP2315780A1 (fr) 2011-05-04
AR072749A1 (es) 2010-09-15
HK1150839A1 (en) 2012-01-13
KR101314369B1 (ko) 2013-10-10
JP5767109B2 (ja) 2015-08-19
EA201100191A1 (ru) 2011-08-30
JP6077587B2 (ja) 2017-02-08
KR101545795B1 (ko) 2015-08-19
US20100021452A1 (en) 2010-01-28
PE20110563A1 (es) 2011-08-29
US20120183529A1 (en) 2012-07-19
US20120195913A1 (en) 2012-08-02
CN102119174B (zh) 2015-01-21
PT2315780E (pt) 2015-11-30
TWI508742B (zh) 2015-11-21
TW201006493A (en) 2010-02-16
JP2011527896A (ja) 2011-11-10
AU2009272771A1 (en) 2010-01-21
BRPI0915928A2 (pt) 2015-11-03
ES2547270T3 (es) 2015-10-05
JO3149B1 (ar) 2017-09-20
IL210485A0 (en) 2011-03-31
HRP20151227T1 (hr) 2015-12-18
CY1116800T1 (el) 2017-03-15
SMP201100010B (it) 2011-09-09
ECSP11010761A (es) 2011-02-28
NZ590057A (en) 2012-08-31
KR20130098432A (ko) 2013-09-04
CL2011000086A1 (es) 2011-07-01
MX2011000616A (es) 2011-02-24
US8106163B2 (en) 2012-01-31

Similar Documents

Publication Publication Date Title
MA32481B1 (fr) Compositions et procédés d'utilisation pour des anticorps thérapeutiques
EP2322557A3 (fr) Compositions et procédés pour traiter des maladies prolifératives
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
MX2011011338A (es) Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
PH12012501549A1 (en) Cd127 binding proteins
MA35661B1 (fr) Inhibiteurs de pak pour le traitement de troubles de prolifération cellulaire
MY177970A (en) Bcma (cd269/tnfrsf17) -binding proteins
SG195082A1 (en) Anti-kir antibodies for the treatment of inflammatory disorders
IL215026A (en) 1r7zb antagonist, methods and compounds @ which include @ the same
EA202092589A2 (ru) Cxcr2-связывающие полипептиды
MX356107B (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
WO2007042309A3 (fr) Generation et profilage d'anticorps therapeutiques derives de hucal gold entierement humains, specifiques de cd38 humain
WO2012118750A3 (fr) Marqueurs biologiques et procédés de prédiction de réponse à des antagonistes de lymphocytes b
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
EA201100452A1 (ru) Лечение воспалительных состояний
MX2014008646A (es) Composiciones utiles como arenas sanitarias para animales.
EP2139497A4 (fr) Procédés pour le traitement d'une lésion et d'une maladie du système nerveux
WO2006125640A3 (fr) Production et profilage d'anticorps therapeutiques entierement humains hucal gold®; propres a la molecule cd38 humaine
JO2796B1 (en) Antiallergic drugs IL-8
SG178976A1 (en) High affinity human antibodies to human protease-activated receptor-2
WO2011098762A8 (fr) Anticorps
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells